Evidence map›Paper›PMID 40335395›Full record

Observational studyEuropean urology oncology2025

Multivitamin Use After Prostate Cancer Diagnosis Is Associated with Lower Risk of Recurrence: A Prospective Cohort Study from the Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).

Kevin Shee, Benjamin E Cedars, Lufan Wang, Stacey A Kenfield, Janet E Cowan, Irina Tolstykh, Crystal S Langlais, William A Pace, Jeanette M Broering, Peter R Carroll and 2 more

Abstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in European urology oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Kevin SheeDepartment of Urology, University of California-San Francisco, San Francisco, CA, USA.
Benjamin E CedarsDepartment of Urology, University of California-San Diego, La Jolla, CA, USA.
Lufan WangDepartment of Urology, University of California-San Francisco, San Francisco, CA, USA.
Stacey A KenfieldDepartment of Urology, University of California-San Francisco, San Francisco, CA, USA; Department of Epidemiology & Biostatistics, University of California-San Francisco, San Francisco, CA, USA.
Janet E CowanDepartment of Urology, University of California-San Francisco, San Francisco, CA, USA.
Irina TolstykhDepartment of Epidemiology & Biostatistics, University of California-San Francisco, San Francisco, CA, USA.
Crystal S LanglaisDepartment of Epidemiology & Biostatistics, University of California-San Francisco, San Francisco, CA, USA; Real World Solutions, IQVIA, Durham, NC, USA.
William A PaceDepartment of Urology, University of California-San Francisco, San Francisco, CA, USA.
Jeanette M BroeringDepartment of Surgery, University of California-San Francisco, San Francisco, CA, USA.
Peter R CarrollDepartment of Urology, University of California-San Francisco, San Francisco, CA, USA.
June M ChanDepartment of Urology, University of California-San Francisco, San Francisco, CA, USA; Department of Epidemiology & Biostatistics, University of California-San Francisco, San Francisco, CA, USA.
Erin L Van BlariganDepartment of Urology, University of California-San Francisco, San Francisco, CA, USA; Department of Epidemiology & Biostatistics, University of California-San Francisco, San Francisco, CA, USA. Electronic address: erin.vanblarigan@ucsf.edu.

Funding

Translational InformaticsP30CA082103 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Alan Ashworth · 1999 to 2026
$209.7M
NCI NIH HHS P30 CA082103
6 · The paper itself

Abstract

BACKGROUND AND

objectiveMultivitamin (MV) use is common among men with prostate cancer (PC). However, data on MV use in relation to the risk of PC recurrence are limited.

methodsWe conducted a longitudinal observational cohort study in 1396 men with nonmetastatic PC who underwent radical prostatectomy (RP) or radiation therapy (RT) and enrolled in the Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE) study between 1999 and 2018. The primary outcome was PC recurrence, defined as biochemical recurrence or initiation of secondary treatment. Postdiagnostic MV use was ascertained via a questionnaire after diagnosis and before any recurrence. Multivariable Cox proportional-hazards regression models controlled for sociodemographic factors, clinical factors, and health behaviors and were used to calculate adjusted hazards ratios (HRs) and 95% confidence intervals (CIs). KEY FINDINGS AND LIMITATIONS: In the study cohort there were 858 (62%) current MV users, 227 (16%) past MV users, and 311 (22%) never users. We observed 119 PC recurrence events over a median follow-up of 4.7 (interquartile range 1.9-9.2) yrs after survey completion. Current MV use was associated with lower risk of PC recurrence (basic model: HR 0.52, 95% CI 0.35-0.78; adjusted model: HR 0.51, 95% CI 0.33-0.78). In stratified analyses, the inverse association between current MV use and PC recurrence was stronger for men with grade group 2 (Gleason 3 + 4) or greater PC (n = 430; HR 0.27, 95% CI 0.13-0.55; p < 0.001) and was not statistically significant for men with grade group 1 (Gleason 3 + 3) PC (n = 966). CONCLUSIONS AND CLINICAL IMPLICATIONS: MV use after PC diagnosis was associated with lower risk of PC recurrence, particularly in patients with higher-grade disease. This finding warrants validation and further investigation.

Indexed as

Neoplasm Recurrence, LocalProstatic NeoplasmsVitaminsAgedCohort StudiesHumansLongitudinal StudiesMaleMiddle AgedProspective StudiesProstatectomyVitaminsMultivitaminsNutritional supplementsProstate cancerRadiation therapyRadical prostatectomyRecurrence

Identifiers

PMID40335395
PMCPMC13549139

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.